GAMMA Investing LLC Acquires 185 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

GAMMA Investing LLC increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 27.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 854 shares of the biotechnology company’s stock after buying an additional 185 shares during the period. GAMMA Investing LLC’s holdings in Sarepta Therapeutics were worth $104,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. CIBC Asset Management Inc grew its holdings in Sarepta Therapeutics by 3.3% during the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after purchasing an additional 86 shares during the period. EP Wealth Advisors LLC grew its holdings in Sarepta Therapeutics by 2.1% during the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 103 shares during the period. Oppenheimer Asset Management Inc. boosted its holdings in shares of Sarepta Therapeutics by 3.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after buying an additional 145 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 16.9% in the third quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 155 shares during the period. Finally, Huntington National Bank boosted its holdings in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $124.79 on Friday. The stock has a market cap of $11.92 billion, a P/E ratio of 99.83 and a beta of 0.77. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock’s 50-day moving average is $122.11 and its 200-day moving average is $131.33. Sarepta Therapeutics, Inc. has a 1-year low of $102.15 and a 1-year high of $173.25.

Analyst Upgrades and Downgrades

SRPT has been the subject of several research analyst reports. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 target price for the company. Piper Sandler reduced their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Robert W. Baird decreased their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average price target of $178.71.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.